Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.24)
# 3,499
Out of 4,883 analysts
112
Total ratings
33.33%
Success rate
-13.14%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Hold | $8 → $8.5 | $9.11 | -6.64% | 6 | Jun 17, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.40 | +609.81% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $129.69 | +23.37% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $134.37 | +63.73% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $5.83 | +260.21% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $9.54 | +162.05% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.40 | +252.94% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $3.38 | +343.79% | 3 | Feb 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $8.34 | +775.30% | 7 | Feb 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.90 | +4,110.30% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $14.45 | +93.84% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $2.72 | +305.16% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $4.00 | +1,975.00% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $7.06 | +98.30% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $11.77 | +70.00% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $21.56 | +53.10% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $14.85 | +910.10% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.03 | - | 2 | Jan 31, 2017 |
Sage Therapeutics
Jun 17, 2025
Maintains: Hold
Price Target: $8 → $8.5
Current: $9.11
Upside: -6.64%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.40
Upside: +609.81%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $129.69
Upside: +23.37%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $134.37
Upside: +63.73%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $5.83
Upside: +260.21%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $9.54
Upside: +162.05%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.40
Upside: +252.94%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $3.38
Upside: +343.79%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $8.34
Upside: +775.30%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.90
Upside: +4,110.30%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.45
Upside: +93.84%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $2.72
Upside: +305.16%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $4.00
Upside: +1,975.00%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $7.06
Upside: +98.30%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $11.77
Upside: +70.00%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $21.56
Upside: +53.10%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $14.85
Upside: +910.10%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.03
Upside: -